Abstract
Background
The postulated benefits of the ketogenic diet in the management of multiple medical conditions have seen more patients who are in therapeutic ketosis attending 18F-FDG PET scans. This study aimed to investigate the effect of ketosis on cerebral glucose metabolism in a clinical PET scanning environment using 18F-FDG uptake as a surrogate marker.
Methods
A retrospective audit was conducted of the brain 18F-FDG uptake in 52 patients who underwent PET scans for possible cardiac sarcoidosis or suspected intracardiac infection, following a ketogenic diet and prolonged fasting. SUVbw for whole brain and separate brain regions was compared with serum glucose and serum ketone body (beta-hydroxybutyrate) levels.
Results
The expected negative association between serum glucose levels and whole brain 18F-FDG uptake was confirmed. A reduction in SUVbw due to increasing serum ketones levels was also observed that was independent of and in addition to the effects of glucose. The magnitude of the reduction in SUVbw related to serum glucose level and serum ketone level was found to be greater in the precuneus than in the cerebellum or whole brain.
Conclusion
In a real-world clinical PET setting, cerebral 18F-FDG uptake appears to be affected by glycaemia and ketonaemia. This means when assessing the brain, both serum glucose and ketone levels need to be considered when SUVs are used to distinguish between pathologic and physiologic states. The magnitude of this effect appears to vary between different brain regions. This regional difference should be taken into consideration when selecting the appropriate brain region for SUV normalisation, particularly when undertaking database comparison in the assessment of dementia.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Ramsay, S. C. 2 ; Malacova, E. 3 ; Bourgeat, P. 4 ; Goodman, S. J. 2 ; Dunn, C. J. 2 ; Robinson, B. M. 2 ; Lee, K. 2 ; Pattison, D. A. 5 1 Royal Brisbane & Women’s Hospital, Department of Nuclear Medicine & Specialised PET Services, Brisbane, Australia (GRID:grid.416100.2) (ISNI:0000 0001 0688 4634); Prince of Wales Hospital, Nuclear Medicine and PET/CT Department, Sydney, Australia (GRID:grid.415193.b)
2 Royal Brisbane & Women’s Hospital, Department of Nuclear Medicine & Specialised PET Services, Brisbane, Australia (GRID:grid.416100.2) (ISNI:0000 0001 0688 4634)
3 QIMR Berghofer Medical Research Institute, Brisbane, Australia (GRID:grid.1049.c) (ISNI:0000 0001 2294 1395)
4 Australian E-Health Research Centre, CSIRO Health and Biosecurity, Brisbane, Australia (GRID:grid.467740.6) (ISNI:0000 0004 0466 9684)
5 Royal Brisbane & Women’s Hospital, Department of Nuclear Medicine & Specialised PET Services, Brisbane, Australia (GRID:grid.416100.2) (ISNI:0000 0001 0688 4634); University of Queensland, School of Medicine, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537)




